Latest News

Lilly is the first pharmaceutical company to reach the trillion-dollar club in response to weight-loss boom

Eli Lilly's market value surpassed $1 trillion on Friday. It is the first pharmaceutical company to join the exclusive club of tech giants, and it highlights its growth as a weight loss powerhouse.

The explosive growth in the weight loss drug market has been a major factor behind the more than 35% increase in the stock price of the company this year.

Obesity treatments, once considered a niche, are now among the most lucrative segments of healthcare. Demand is steadily increasing.

Novo Nordisk was the first to market, but Lilly’s drugs Mounjaro & Zepbound have grown in popularity & helped Lilly surpass its competitor in prescriptions.

Lilly's obesity and diabetes business generated combined revenues of over $10.09 billion in the last reported quarter. This represents more than half its total revenue, which was $17.6 Billion.

Kevin Gade is the chief operating officer of Lilly shareholder Bahl and Gaynor. He spoke ahead of this milestone.

Wall Street predicts that the global weight-loss drugs market will be worth $150 billion in 2030. Lilly and Novo are expected to control the majority of the projected sales.

Investors now focus on Lilly’s orforglipron oral obesity drug which is expected be approved in early 2019.

Citi analysts wrote in a note published last week that the latest generation GLP-1 drugs are already a "sales phenomena" and orforglipron will benefit from "the gains made by its predecessors who were injectables."

Lilly's recent agreement with the White House, which will lower prices for its weight loss drugs and also include planned investments in expanding drug production bodes well for its future growth.

James Shin, Director of Biopharma Equity Analysis at Deutsche Bank said that Lilly has started to resemble "the Magnificent Seven", referring to tech giants such as Nvidia and Microsoft, which have fueled much of this year's market returns.

Investors once regarded it as a member of this elite group, but after some disappointing earnings and headlines, it fell out of favor.

He added that it now appears poised to return, perhaps even as a viable alternative for investors. Recent concerns and weakness of some AI stocks have also contributed to this.

Analysts and investors will be watching to see if Lilly is able to maintain its current growth, as the prices of Mounjaro, Zepbound, and its diversified pipeline come under pressure. They'll also be looking at whether its dealmaking and scale-up plan can offset margin pressure. (Reporting and editing by Sriraj Kalluvila and Devika Syamnath in Bengaluru.

(source: Reuters)